Please login to the form below

How can pharma help the NHS drive much-needed change in mental health services?

Laurence Mascarenhas, of Wilmington Healthcare, assesses how pharma can help the NHS to achieve Parity of Esteem (PoE) in mental health

Introduction
 

One in four British adults will suffer at least one mental health disorder in any given year; 1.2m people in England have a learning disability and more than one million people will have dementia by 2021.* However, despite the prevalence of mental health problems, only a quarter of people with illnesses, such as depression, are receiving treatment, according to NHS England.  

Tackling the issues that lie behind these statistics and ensuring that mental health is given the same priority as physical health is now a key Government priority, driven by NHS England’s Parity of Esteem (PoE) Programme. The PoE programme aims to achieve this through prevention, early intervention, access to crisis care on a 24/7 basis and better integration of mental and physical healthcare.  

What are the key barriers to PoE?
 

There is still a lot of stigma attached to mental health problems and although the situation is slowly improving, many people refuse to seek help for fear of discrimination at home and at work.    

If individuals do visit their GP, opportunities to refer them on to appropriate care are often missed because many GPs have a limited understanding of the complexity of mental health and they may also be unaware of the services available in their local area.  

Furthermore, while it is widely accepted that physical and mental health problems often go hand in hand, they tend to be treated in isolation by healthcare professionals. The fact that the police, Social Services, mental health and other NHS services work in isolation is also a problem.  

Changes that could help to achieve PoE
   

Early intervention is key and GPs should be looking to refer patients to services such as Improving Access to Psychological Therapies (IAPTs) - a 16-week programme designed for people with anxiety and depression that can be accessed via all mental health trusts in England.  
 

If one GP in each practice held a specific qualification, such as a mental health diploma, this could dramatically increase the number of patients diagnosed within primary care and referred to appropriate services.  

A more integrated approach is needed for mental and physical healthcare. This would see, for example, those with long-term physical health problems getting regular reviews of their mental health, and people with mental health issues receiving appropriate intervention and support to address associated physical health risk behaviours. 
 

Joined up working between the NHS, police and Social Services is essential, and there should also be a greater emphasis on rehabilitation; Recovery Colleges should be a key part of the patient pathway to help people get back on track and promote self-care.

How can pharma help?
 

There is a big role for pharma in funding research and conducting clinical trials to further explore the side effects of drugs which are used for conditions, ranging from diabetes to dementia, and are known to cause psychosis.  

The cash-strapped NHS has a culture of prescribing the cheapest drugs. Pharma needs to convince commissioners and providers of the value of mental health drugs, which may be more expensive to buy, but will save money in the long-run because they are more effective.
 

Pharma can also provide support with adherence by making medicines and the administration of them more user-friendly.  It could also offer training for care workers to help ensure that people with mental health conditions take their medicines as prescribed.  
 

Data is also key. By analysing the wealth of patient data that already exists, such as Hospital Episodes Statistics (HES) data and Mental Health and Learning Disabilities Data, pharma can identify important trends, gaps and needs that will lead to significant improvements in patient care.  

Conclusion
 

To help improve treatments and outcomes in mental health, pharma could: fund research and conduct clinical trials to further explore the side effects of drugs; educate commissioners and providers on the efficacy and long-term savings that can be generated from specific drugs, and provide support on adherence. In addition, the industry can harness the power of data to help the NHS identify trends and opportunities to make a real difference to patient care and outcomes.
   

                                                                  Ends

*Statistics from NHS England https://www.england.nhs.uk/mentalhealth/parity
 

Laurence Mascarenhas is an Associate Director at Wilmington Healthcare.
For information on Wilmington Healthcare, log on to www.wilmingtonhealthcare.com
 

5th January 2017

Share

Tags

Company Details

Wilmington Healthcare

01268 495600

Contact Website

Address:
Beechwood House
2-3 Commercial Way
Christy Close
Southfields
Basildon
SS15 6EF
United Kingdom

Latest content on this profile

Wilmington Healthcare appoints new Commercial Director
Healthcare intelligence provider Wilmington Healthcare, which incorporates HSJ, Binley’s, OnMedica and Wellards, has appointed Sue Plant as Commercial Director for MedTech.
Wilmington Healthcare
How can pharma support NHS service change?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, find some answers in NHS England guidance for commissioners
Wilmington Healthcare
Sir Bruce Keogh is appointed chair of judges for HSJ Awards
Sir Bruce Keogh, the former National Medical Director for NHS England, will chair the judges’ panel for the 37th annual HSJ Awards – the world’s largest healthcare awards programme.
Wilmington Healthcare
How will new data protection law affect pharma?
Sarah Eglington, of Wilmington Healthcare, explores how GDPR will change pharma’s relationship with healthcare professionals
Wilmington Healthcare
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare
Wilmington Healthcare
How can pharma engage with key decision-makers in new, collaborative NHS care models?
Paul Midgley, Sue Thomas, Steve How and Oli Hudson, of Wilmington Healthcare, explore how pharma should adapt its approach
Wilmington Healthcare